share_log

Ocugen | 10-Q: Q3 2024 Earnings Report

Ocugen | 10-Q: Q3 2024 Earnings Report

Ocugen | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/15 04:32

Moomoo AI 已提取核心訊息

Ocugen reported Q3 2024 revenue of $1.1 million, down 69% from $3.7 million in Q3 2023, with a net loss of $13.0 million compared to $11.7 million last year. Research and development expenses increased 15% to $8.1 million, while general and administrative costs decreased 31% to $6.3 million. The company ended the quarter with $38.7 million in cash.The company made significant progress on its gene therapy pipeline, with OCU400 now in Phase 3 trials for retinitis pigmentosa and receiving expanded access program approval from FDA. OCU410 is advancing in Phase 2 trials for age-related macular degeneration, while OCU410ST completed Phase 1 for Stargardt disease. The FDA also lifted the clinical hold on OCU200's IND application.Subsequent to quarter end, Ocugen secured $29.2 million in debt financing from Avenue Capital to support ongoing development programs. However, management indicated current cash levels are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern without raising significant additional capital.
Ocugen reported Q3 2024 revenue of $1.1 million, down 69% from $3.7 million in Q3 2023, with a net loss of $13.0 million compared to $11.7 million last year. Research and development expenses increased 15% to $8.1 million, while general and administrative costs decreased 31% to $6.3 million. The company ended the quarter with $38.7 million in cash.The company made significant progress on its gene therapy pipeline, with OCU400 now in Phase 3 trials for retinitis pigmentosa and receiving expanded access program approval from FDA. OCU410 is advancing in Phase 2 trials for age-related macular degeneration, while OCU410ST completed Phase 1 for Stargardt disease. The FDA also lifted the clinical hold on OCU200's IND application.Subsequent to quarter end, Ocugen secured $29.2 million in debt financing from Avenue Capital to support ongoing development programs. However, management indicated current cash levels are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern without raising significant additional capital.
Ocugen報告2024年第三季度營業收入爲110萬美元，比2023年第三季度的370萬美元下降了69%，淨虧損爲1300萬美元，而去年爲1170萬美元。研發費用增加了15%，達到810萬美元，而管理費用下降了31%，爲630萬美元。公司在季度末現金餘額爲3870萬美元。該公司在基因治療管線方面取得了重大進展，OCU400目前正在進行視網膜色素變性治療的三期試驗，並獲得FDA的擴展接入程序批准。OCU410在治療年齡相關性黃斑變性的二期試驗中取得進展，而OCU410ST完成了針對斯塔加特病的一期試驗。FDA還解除對OCU200的IND申請的臨牀持有。在季度結束後，Ocugen從Avenue Capital獲得了2920萬美元的債務融資，以支持正在進行的開發項目。然而，管理層表示目前的現金水平不足以支持未來12個月的運營，給公司是否能夠在沒有大規模額外資本的情況下繼續經營帶來了重大疑慮。
Ocugen報告2024年第三季度營業收入爲110萬美元，比2023年第三季度的370萬美元下降了69%，淨虧損爲1300萬美元，而去年爲1170萬美元。研發費用增加了15%，達到810萬美元，而管理費用下降了31%，爲630萬美元。公司在季度末現金餘額爲3870萬美元。該公司在基因治療管線方面取得了重大進展，OCU400目前正在進行視網膜色素變性治療的三期試驗，並獲得FDA的擴展接入程序批准。OCU410在治療年齡相關性黃斑變性的二期試驗中取得進展，而OCU410ST完成了針對斯塔加特病的一期試驗。FDA還解除對OCU200的IND申請的臨牀持有。在季度結束後，Ocugen從Avenue Capital獲得了2920萬美元的債務融資，以支持正在進行的開發項目。然而，管理層表示目前的現金水平不足以支持未來12個月的運營，給公司是否能夠在沒有大規模額外資本的情況下繼續經營帶來了重大疑慮。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Nkarta
    NKTX
    -- 1.970
    Soleno Therapeutics
    SLNO
    -- 67.3900
    NuCana
    NCNA
    -- 1.0700
    ImmunityBio
    IBRX
    -- 3.360
    Marker Therapeutics
    MRKR
    -- 1.3700
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點